Acerta Pharma

Executive Summary

Acerta Pharma, a European R&D center of AstraZeneca based in Oss, Netherlands, specializes in discovering and developing innovative small molecule therapies for hematological malignancies. Leveraging covalent binding technology and deep oncology expertise, the company has created highly selective targeted therapies, most notably acalabrutinib (Calquence), a next-generation BTK inhibitor approved for B-cell malignancies such as chronic lymphocytic leukemia and mantle cell lymphoma. Fully integrated into AstraZeneca's global oncology network, Acerta continues to advance a pipeline of covalent inhibitors aimed at improving outcomes for blood cancer patients. The company's strong foundation in structure-based drug design and its alignment with AstraZeneca's strategic priorities position it as a key contributor to novel oncology treatments, with ongoing research focusing on overcoming resistance mechanisms and expanding therapeutic indications. As a subsidiary of AstraZeneca, Acerta's financial and operational stability is underpinned by its parent company's resources. Near-term value drivers include clinical data readouts for acalabrutinib in combination regimens, regulatory decisions in new geographies or indications, and progress on early-stage covalent inhibitors targeting undrugged nodes in hematological pathways. While the company does not operate independently, its innovation pipeline and integration with AstraZeneca's development engine provide a clear trajectory for sustained impact in the hematology-oncology space.

Upcoming Catalysts (preview)

• Q3 2026Phase 3 data for acalabrutinib combination in first-line CLL75% success
• Q4 2026Regulatory approval for acalabrutinib in new indication (e.g., WM or MZL)70% success
• TBDIND filing for next-generation covalent inhibitor targeting novel hematological target60% success